APONTIS PHARMA and Zentiva Sign Investment Agreement

On October 16, 2024, APONTIS PHARMA AG and Zentiva Pharma GmbH announced an investment agreement aimed at fostering APONTIS PHARMA’s growth. As part of this agreement, Zentiva will issue a voluntary public purchase offer for all outstanding shares of APONTIS PHARMA at EUR 10.00 per share in cash. The offer document will be accessible at www.zentiva-offer.com.

The offer requires regulatory approvals and a minimum acceptance of 65% of shares. Zentiva has already secured approximately 37.5% of shares through an agreement with the main shareholder. Both the Executive and Supervisory Boards of APONTIS PHARMA support the offer and plan to tender their shares.

This move may lead to the cancellation of APONTIS PHARMA shares from OTC trading, pending the Executive Board's fiduciary duties. The offer is not under the German Securities Acquisition and Takeover Act.